Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis

There is growing evidence that the ghrelin axis, including ghrelin (GHRL) and its receptor, the growth hormone secretagogue receptor (GHSR), play a role in cancer progression. Ghrelin gene and ghrelin receptor gene polymorphisms have been reported to have a range of effects in cancer, from increased...

Full description

Saved in:
Bibliographic Details
Published in:BMC genetics 2014-11, Vol.15 (1), p.118-118, Article 118
Main Authors: Pabalan, Noel A, Seim, Inge, Jarjanazi, Hamdi, Chopin, Lisa K
Format: Article
Language:English
Subjects:
Analysis
Breast cancer
Breast Neoplasms - genetics
Cancer
Colorectal Neoplasms - genetics
Confidence intervals
Esophageal Neoplasms - genetics
Genes
Genetic aspects
Genetic Predisposition to Disease
Growth hormones
Health aspects
Humans
Insulin
Lymphoma, Non-Hodgkin - genetics
Meta-analysis
Metabolism
Oncology, Experimental
Polymorphism, Single Nucleotide
Population
Prostate cancer
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is growing evidence that the ghrelin axis, including ghrelin (GHRL) and its receptor, the growth hormone secretagogue receptor (GHSR), play a role in cancer progression. Ghrelin gene and ghrelin receptor gene polymorphisms have been reported to have a range of effects in cancer, from increased risk, to protection from cancer, or having no association. In this study we aimed to clarify the role of ghrelin and ghrelin receptor polymorphisms in cancer by performing a meta-analysis of published case-control studies. In the overall analysis, homozygous and recessive associations indicated that the minor alleles of rs696217 and rs2075356 GHRL polymorphisms conferred reduced cancer risk (odds ratio [OR] 0.61-0.78). The risk was unchanged for breast cancer patients when analysed separately (OR 0.73-0.83). In contrast, the rs4684677 GHRL and the rs572169 GHSR polymorphisms conferred increased breast cancer risk (OR 1.97-1.98, p = 0.08 and OR 1.42-1.43, p = 0.08, respectively). All dominant and co-dominant effects showed null effects (OR 0.96-1.05), except for the rs572169 co-dominant effect, with borderline increased risk (OR 1.08, p = 0.05). This study suggests that the rs696217 and rs2075356 ghrelin gene (GHRL) polymorphisms may protect carriers against breast cancer, and the rs4684677 GHRL and rs572169 GHSR polymorphisms may increase the risk among carriers. In addition, larger studies are required to confirm these findings.
ISSN:1471-2156
1471-2156
DOI:10.1186/s12863-014-0118-3